JPH02188571A - 化合物 - Google Patents

化合物

Info

Publication number
JPH02188571A
JPH02188571A JP1257612A JP25761289A JPH02188571A JP H02188571 A JPH02188571 A JP H02188571A JP 1257612 A JP1257612 A JP 1257612A JP 25761289 A JP25761289 A JP 25761289A JP H02188571 A JPH02188571 A JP H02188571A
Authority
JP
Japan
Prior art keywords
formula
fluorophenyl
group
methylethyl
imidazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP1257612A
Other languages
English (en)
Japanese (ja)
Inventor
Nigel S Watson
ナイジエル・ステイーブン・ウオトソン
Chuen Chan
チユーエン・チヤン
Barry C Ross
バリー・クライブ・ロス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB888823191A external-priority patent/GB8823191D0/en
Priority claimed from GB888823192A external-priority patent/GB8823192D0/en
Priority claimed from GB898902847A external-priority patent/GB8902847D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JPH02188571A publication Critical patent/JPH02188571A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP1257612A 1988-10-03 1989-10-02 化合物 Pending JPH02188571A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB8823192.3 1988-10-03
GB888823191A GB8823191D0 (en) 1988-10-03 1988-10-03 Chemical compounds
GB8823191.5 1988-10-03
GB888823192A GB8823192D0 (en) 1988-10-03 1988-10-03 Chemical compounds
GB8902847.6 1989-02-09
GB898902847A GB8902847D0 (en) 1989-02-09 1989-02-09 Chemical compounds

Publications (1)

Publication Number Publication Date
JPH02188571A true JPH02188571A (ja) 1990-07-24

Family

ID=27264106

Family Applications (1)

Application Number Title Priority Date Filing Date
JP1257612A Pending JPH02188571A (ja) 1988-10-03 1989-10-02 化合物

Country Status (19)

Country Link
US (2) US5013749A (OSRAM)
JP (1) JPH02188571A (OSRAM)
KR (1) KR900006297A (OSRAM)
AU (1) AU628862B2 (OSRAM)
BE (1) BE1003007A3 (OSRAM)
CH (1) CH680442A5 (OSRAM)
DE (1) DE3932887A1 (OSRAM)
DK (1) DK483689A (OSRAM)
ES (1) ES2019163A6 (OSRAM)
FI (1) FI894648A7 (OSRAM)
FR (1) FR2637183A1 (OSRAM)
GB (1) GB2223224B (OSRAM)
GR (1) GR890100634A (OSRAM)
IT (1) IT1237470B (OSRAM)
LU (1) LU87600A1 (OSRAM)
NL (1) NL8902441A (OSRAM)
NO (1) NO893909L (OSRAM)
PT (1) PT91878B (OSRAM)
SE (1) SE8903226L (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3913725A1 (de) * 1989-04-26 1990-10-31 Basf Ag 1-halogenvinyl-azole und diese enthaltende fungizide und wachstumsregulatoren
EP0422895A1 (en) * 1989-10-10 1991-04-17 Glaxo Group Limited Chemical compounds
PL361097A1 (en) * 2000-10-12 2004-09-20 Nissan Chemical Industries, Ltd. Preventives and remedies for complications of diabetes
IL158300A0 (en) * 2001-04-27 2004-05-12 Bristol Myers Squibb Co Bisarylimidazol derivatives and pharmaceutical compositions containing the same
KR20060133013A (ko) * 2004-04-16 2006-12-22 워너-램버트 캄파니 엘엘씨 신규 이미다졸
US20050282883A1 (en) * 2004-04-29 2005-12-22 John Griffin Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US7163945B2 (en) * 2004-04-29 2007-01-16 Pharmix Corp. Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20060084695A1 (en) * 2004-04-29 2006-04-20 John Griffin Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US7199126B2 (en) 2004-04-29 2007-04-03 Pharmix Corporation Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US7183285B2 (en) * 2004-04-29 2007-02-27 Pharmix Corp. Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20050272770A1 (en) * 2004-04-29 2005-12-08 John Griffin Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
WO2005115397A2 (en) * 2004-04-29 2005-12-08 Pharmix Corporation Compositions and treatments for modulating kinase and/or hmg-coa reductase
US20060111436A1 (en) * 2004-11-23 2006-05-25 John Griffin Compositions and treatments for modulating kinase and/or HMG-CoA reductase
US8372877B2 (en) 2010-04-16 2013-02-12 Cumberland Pharmaceuticals Stabilized statin formulations
EP2626069A4 (en) 2010-10-06 2014-03-19 Univ Tokyo Prophylactic and/or therapeutic agent against lymphedema

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4647576A (en) * 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
US4668794A (en) * 1985-05-22 1987-05-26 Sandoz Pharm. Corp. Intermediate imidazole acrolein analogs
HUT48208A (en) * 1985-10-25 1989-05-29 Sandoz Ag Process for producing heterocyclic analogues of mevalolactone derivatives and pharmaceutical compositions comprising such compounds
EP0244364A3 (en) * 1986-04-30 1992-04-01 Sandoz Ag Preparation of olefinic compounds
DE3800785A1 (de) * 1988-01-09 1989-07-20 Hoechst Ag Substituierte 7-(pyridazin-5-yl)-3,5-dihydroxyheptan(en)- saeuren, ihre entsprechenden (delta)-lactone bzw. derivate, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, pharmazeutische praeparate und zwischenprodukte
NO890522L (no) * 1988-02-25 1989-08-28 Bayer Ag Substituerte imidazolinoner og imidazolinthioner.

Also Published As

Publication number Publication date
AU4243189A (en) 1990-04-05
PT91878A (pt) 1990-04-30
AU628862B2 (en) 1992-09-24
CH680442A5 (OSRAM) 1992-08-31
KR900006297A (ko) 1990-05-07
DK483689A (da) 1990-04-04
NL8902441A (nl) 1990-05-01
DK483689D0 (da) 1989-10-02
SE8903226L (sv) 1990-04-04
FI894648A0 (fi) 1989-10-02
LU87600A1 (fr) 1990-05-15
FR2637183A1 (fr) 1990-04-06
DE3932887A1 (de) 1990-04-05
IT8948424A0 (it) 1989-10-02
GB2223224B (en) 1992-01-08
NO893909D0 (no) 1989-10-02
FI894648L (fi) 1990-04-04
SE8903226D0 (sv) 1989-10-02
BE1003007A3 (fr) 1991-10-22
IT1237470B (it) 1993-06-07
NO893909L (no) 1990-04-04
US5120848A (en) 1992-06-09
PT91878B (pt) 1995-05-31
GR890100634A (el) 1990-11-29
FI894648A7 (fi) 1990-04-04
US5013749A (en) 1991-05-07
GB2223224A (en) 1990-04-04
GB8922212D0 (en) 1989-11-15
IT8948424A1 (it) 1991-04-02
ES2019163A6 (es) 1991-06-01

Similar Documents

Publication Publication Date Title
FI96859B (fi) Menetelmä terapeuttisesti käyttökelpoisten fungisidisten triatsoliyhdisteiden valmistamiseksi
JP2853227B2 (ja) ７置換‐ヘプト‐６‐エン酸、ヘプタン酸及び誘導体並びにそれらの中間体の製法
JPH02188571A (ja) 化合物
JP2007197460A (ja) 高コレステロール血症治療用の医薬組成物
JPH0641448B2 (ja) ３−デメチルメバロン酸誘導体
EP0252476B1 (en) Trans-6-[2-(N-heteroaryl-3,5-disubstituted) pyrazol-4-yl)-ethyl]- or ethenyl] tetrahydro-4-hydroxypyran-2-one-derivatives a process for their preparation and the use thereof
CN114269755A (zh) 作为magl抑制剂的4,4a,5,7,8,8a-六吡啶并[4,3-b][1,4]噁嗪-3-酮化合物
JPH04210682A (ja) 酵素ＨＭＧ−ＣｏＡレダクターゼの抑制剤として活性な化合物ならびに該化合物を含む医薬組成物
EA013184B1 (ru) Конденсированные производные пиразола и способы лечения с их помощью заболеваний, вызванных нарушением обмена веществ
JPH02250870A (ja) コレステロール生合成抑制性化合物
JPH03167187A (ja) ヘテロ環化合物
JPH04230381A (ja) 置換されたピロロ−ピリジン類
CN1312135C (zh) 三环三唑并苯并氮杂䓬衍生物、用于制备该衍生物的方法和抗变态反应剂
AU8022187A (en) Azaindole and indolizine derivatives, processes for their production and their use as pharmaceuticals
PH26675A (en) Pyrimidinyl substituted hydroxyacids lactones and esters and pharmaceutical compositions containing them
JPH01261377A (ja) 置換されたピリミジン
NL8502010A (nl) Nafthylanaloga van mevalonolacton en derivaten daarvan, werkwijzen voor hun bereiding en farmaceutische preparaten die ze bevatten.
US5112819A (en) Imidazole derivatives, pharmaceutical compositions and use
US5055484A (en) 7(1h-pyrrol-3-yl)-substituted 3,5-dihydroxyhept-6-enoic acids, 7-(1h-pyrrol-3-yl)-substituted 3,5-dihyroxyhept-anoic acids, their corresponding delta-lactones and salts, their use as medicaments and pharmaceutical products and intermediates
JPH06501918A (ja) ピロロピリダジン化合物
JPS6251641A (ja) ３−デメチルメバロン酸誘導体
JPH01261375A (ja) 置換イミダゾリノン類又はイミダゾリチオン類
JPS5920286A (ja) β−ラクタム抗生物質の新規なカルボン酸エステル類
CN100387580C (zh) 三环三唑并苯并氮杂䓬衍生物、用于制备该衍生物的方法和抗变态反应剂
JP2003327578A (ja) 光学活性２−フェニル−２，３−ジヒドロキシプロピルアゾール誘導体の製造法